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Abstract
Background: Primary refractory disease is a main challenge in the management of non-Hodgkin’s Lymphoma (NHL). This
survey was performed to define the rate of refractory disease to first-line therapy in B and T-cell NHL subtypes and the long-
term survival of primary refractory compared to primary responsive patients.
Methods: Medical records were reviewed of 3,106 patients who had undergone primary treatment for NHL between 1982
and 2012, at the Hematology Centers of Torino and Bergamo, Italy. Primary treatment included CHOP or CHOP-like
regimens (63.2%), intensive therapy with autograft (16.9%), or other therapies (19.9%). Among B-cell NHL, 1,356 (47.8%)
received first-line chemotherapy with rituximab. Refractory disease was defined as stable/progressive disease, or transient
response with disease progression within six months.
Results: Overall, 690 (22.2%) patients showed primary refractory disease, with a higher incidence amongst T-cell compared
to B-cell NHL (41.9% vs. 20.5%, respectively, p,0.001). Several other clinico-pathological factors at presentation were
variably associated with refractory disease, including histological aggressive disease, unfavorable clinical presentation, Bone
Marrow involvement, low lymphocyte/monocyte ration and male gender. Amongst B-cell NHL, the addition of rituximab
was associated with a marked reduction of refractory disease (13.6% vs. 26.7% for non-supplemented chemotherapy, p,
0.001). Overall, primary responsive patients had a median survival of 19.8 years, compared to 1.3 yr. for refractory patients. A
prolonged survival was consistently observed in all primary responsive patients regardless of the histology. The long life
expectancy of primary responsive patients was documented in both series managed before and after 2.000. Response to
first line therapy resulted by far the most predictive factor for long-term outcome (HR for primary refractory disease: 16.52,
p,0.001).
Conclusion: Chemosensitivity to primary treatment is crucial for the long-term survival in NHL. This supports the necessity
of studies aimed to early identify refractory disease and to develop different treatment strategies for responsive and
refractory patients.
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Introduction
Despite improvements in the efficacy of the available treat-
ments, there is a variable proportion of non-Hodgkin’s Lymphoma
(NHL) patients displaying very poor or transient response to
primary treatment. [1–3] These patients have primary refractory
disease. At present, primary refractoriness remains a challenge in
the management of malignant lymphoma. [4,5] In fact, several
studies are investigating molecular markers that may be associated
with refractory disease. [6–11] These markers might allow for
early diagnosis, as well as the identification of novel therapeutic
targets. [12–14] Moreover, alternative treatment options are
sought in order to improve the usually poor outcome for refractory
lymphoma patients. [15–17].
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Although response to primary treatment has relevant clinical
implications, there are several open issues regarding primary
refractory disease. In particular, it has to be determined: (i) the real
proportion of refractory patients amongst the various lymphoma
subgroups; (ii) the influence of the presently available treatments
on the rate of refractory disease; (iii) the actual long-term survival
of primary responsive compared to primary refractory patients.
To address these issues, we performed a long-term, retrospective
survey on 3,106 NHL patients that had been managed over the
last three decades. Aims of the study were to define the rate of
responsiveness among patients requiring primary systemic treat-
ment for their newly diagnosed malignant lymphoma, and to
outline the impact of the response to primary treatment on the
overall survival.
Methods
Data sources, patient population, and clinical procedures
The retrospective review was performed on newly diagnosed,
NHL patients, admitted and managed at the University Hema-
tology of Torino (S. Giovanni Battista and Mauriziano Hospitals)
and at the Hematology Division of Ospedali Riuniti of Bergamo,
Italy, during the last three decades (1982–2012). An electronic
database has been used since early 1980 s at the Hematology
Division of Bergamo. [18] A similar database has been used since
2000 at the University Department of Hematology in Torino. [19]
Based on these registries, data have been collected of 3,393 NHL
patients requiring systemic therapy. The retrospective analysis was
approved by our local Ethical Committee (Ospedale Infantile
Regina Margherita [O.I.R.M.]/Sant’Anna - Ordine Mauriziano,
Torino) (prot.No. 100355/A210). The Ethical Committee did not
require a written informed consent form for the patients included
in the analysis. However, patient information was anonymized in
the recorded files.
All patients underwent common diagnostic procedures, in order
to define the type of lymphoma and disease extension, and then to
evaluate response to treatment. A total of 3,393 patients entered in
our data base, however information on response to primary
treatment was lacking for 78 (2.3%) of them and overall3,315
could be considered for the analysis. In addition, 209 patients
(6.3%), with a median age of 69 (range, 20–98), died early (within
8 months) during or before any treatment was given, and could not
be properly evaluated for response. Causes of early death were: i.
early, treatment related toxicities (n = 163, 4.9% of the whole
series), including cardiac, hepatic, renal, pulmonary or infectious
causes; ii. other cancers (n = 8, 0.2%); iii. unknown reasons (n = 17,
0.5%); iv. probable but not formally proven lymphoma progres-
sion (n= 21, 0.6%). Thus, we were able to complete an extensive
analysis on response to primary systemic treatment on 3,106
patients.
All patients received chemotherapy, with or without rituximab,
depending on the time of diagnosis in relationship to the time of
rituximab availability in the clinical setting. [20,21] Overall,
patients were managed with three main treatment strategies: (i)
CHOP or CHOP-like schedules, including MACOP-B, VACOP,
ACOP, CNOP, COMP, and CHOEP; [22,23] (ii) high-dose
sequential program with autograft (HDS regimen); [19] (iii) a
miscellaneous group of other therapies, mostly including the
different schedules that are variously employed for low-grade
lymphoma, such as single-agents, Chlorambucil, Fludarabine,
Cladribine, Mechlorethamine, Cyclophosphamide, Bendamus-
tine, or combination schedules, such as CVP, FND, DHAP,
MINE, or intensive programs (BFM or Magrath-schedule) for
Burkitt’s or Burkitt-like lymphoma. [1,4,24–26].
Study outcomes
The main objectives of the study were: (i) to define the rate of
primary refractory disease; (ii) to evaluate the clinical and
therapeutic factors associated with refractory disease; and (iii) to
investigate the overall survival (OS) of refractory vs. responsive
patients, according to Cheson criteria. [27] Refractory disease was
defined as:
i. stable or progressive disease (fully refractory), following front-
line therapy, either completed or discontinued in order to shift
to an intensified salvage program;
ii. transient response with disease progression within six months
(early progression), following first-line chemotherapy.
Statistical analysis
Patient characteristics were tested using the Fisher’s exact test
for categorical variables and the Mann-Whitney test for contin-
uous ones. For univariate survival analyses, the OS curves were
first estimated by the Kaplan-Meier method, and compared using
the log-rank test, then the Cox proportional hazards model was
used to compare risk factors by the Wald test [28,29]. Comparison
included the following parameters: gender, age at diagnosis (.60
vs. #60 yrs), histological subtypes, IPI score (3–5 vs. 0–2), bone
marrow (BM) involvement, rituximab administration, lymphocyte
to monocyte ratio at diagnosis (#2.6 vs. 2.6) [30], presence and
type of primary refractory disease, and the administration of HDS
front-line. The multivariate Cox model was also used to assess the
effects of these risk factors on OS; all the above-mentioned
covariates, except gender, were treated as time-dependent
variables, similar to the univariate ones. At last, the same
predictors were used as independent variables in different
univariate and multivariate binary logistic regression models, in
order to identify the possible risk factors for the status of
refractoriness (dependent variable); these results are presented as
OR and 95% CIs. The diagnostic performances of these models
are expressed as accuracy, sensitivity, specificity, and positive/
negative predictive values. All reported p-values were two-sided, at
the conventional 5% significance level. Data were analyzed as of
October 2013, using IBM SPSS 21.0.0 and R 3.0.0. At the time of
analysis, there were 1,864 (60%) patients known to be alive: 1,508
(80.9%) of them had been seen in the clinic or had been contacted
by phone at least once over the last 18 mos., whereas 356 (19.1%)
patients had been followed for a median of 6.5 years (range 0.5–29
years), afterwards they discontinued the follow up.
Results
The main clinical characteristics of the whole series of 3,315
patients that were analyzed are summarized in Table 1. There
were no significant differences in the distribution of the main
clinical parameters between the Bergamo and Torino Centers. All
patients who had undergone primary systemic treatment were
considered eligible for the study, including patients with very
advanced age. Indeed, there were 148 patients (4.5%) over 80
years old. Among initial 3,315 patients, 209 patients had an early
death, mainly due to toxicity (see Patients and Methods and
Table 1). Thus, the rate of response to first line therapy could be
properly determined in 3,106 patients.
Raw incidence of refractory disease
As reported in Table 2, 690 (22.2%) out of 3,106 assessable
patients showed refractory disease, with similar frequencies in
Bergamo and Torino Centers. A markedly higher raw incidence of
Primary Refractory Disease in Non-Hodgkin’s Lymphoma
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refractory disease was observed amongst T-cell compared to B-cell
NHL (41.9% vs. 20.5%, respectively, p,0.001). In addition,
aggressive disease, defined in terms of either histology or clinical
prognostic presentation, was associated with significantly increased
incidence of refractory disease. Female patients were slightly, but
significantly, more responsive than male patients. By contrast, the
overall frequency of refractory patients was not significantly
influenced by age (23.1%, above 60 years, vs. 21.5%, 60 or
Table 1. Characteristics of the Study Cohort.
Characteristic Patients (N = 3,315)1
Age – yr median (range) 59 (15–98)
Male sex – no. (%) 1,808 (54.5)
Histology - no. (%)
N B cell 3,066(92.5)
N T cell 249(7.5)
B-cell subtypes2– no. (%)
N DLB-CL 1,694 (55.3)
N FL 607 (19.8)
N MCL 196 (6.4)
N Miscellaneous 569(18.5)
Histological grade3 - no. (%)*
N low grade 992 (29.9)
N intermediate/high grade 2,322 (70.1)
Ann Arbor Stage - no. (%)**
N I–II 1,070 (33)
N III–IV 2,172 (67)
BM involvement - no. (%)***
N NO 1,818 (65.2)
N YES 971 (34.8)
LDH serum level - no. (%){
N normal 1,657 (58.7)
N high 1,167 (41.3)
IPI score4 - no. (%){{
N 0–2 1,448 (58)
N 3–5 1049 (42)
LM ratio5 - no. (%)`
N .2.6 1,281 (59.3)
N #2.6 879 (40.7)
Chemotherapy schedule6 - no. (%){{{
N CHOP or CHOP-like 2,089 (64)
N HDT and autograft 529 (16.2)
N other schemes 648 (19.8)






1Among 3,315 assessable patients in our data base, 209 died early, due to early toxic death (n = 163, 4.9%), other cancers (n = 8, 0.2%), unknown reasons (n = 17),
probable but not formally proven lymphoma progression (n = 21); overall, 3,106 could be properly evaluated for response to therapy;2B-cell lymphoma was classified
into four groups, i.e.: Diffuse Large B-Cell Lymphoma (DLB-CL), Follicular Lymphoma (FL), Mantle-Cell Lymphoma (MCL), and miscellaneous histologies, including
marginal-zone (MZL), small lymphocytic (SL), and Burkitt’s and lymphoblastic lymphoma; 3low-grade lymphoma included FL-MZL-SL-low-grade T-cell lymphoma, all
remaining subtypes, i.e. MCL, DLCL, transformed-FL, high-grade peripheral T-cell NHL, other aggressive histotypes (Burkitt’s and Burkitt-like NHL, Lymphoblastic
lymphoma) were included among intermediate/high-grade histologies; 4IPI: International Prognostic Index: assessed in all diffuse large-cell lymphoma, and low-grade
lymphoma; 5the Lymphocyte to Monocyte (LM) ratio was assessed at diagnosis by automatic blood count; 6Chemotherapy was delivered to all patients, according to
various schedules, as detailed in the text.
missing values: * = 1; ** = 73 (2.2%); *** = 526 (15.9%); {= 491 (14.8%); {{ (including cases where IPI was NA) = 818 (24.7%); `= 1,155 (34.8%); {{{= 49 (1.5%); 1= 66 (2.1%).
doi:10.1371/journal.pone.0106745.t001
Primary Refractory Disease in Non-Hodgkin’s Lymphoma
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e106745
younger). Lastly, an intensive primary therapy with autograft was
associated with a significantly higher response compared to
conventional chemotherapy regimens (overall refractory disease:
19% vs. 22.7%, respectively, p=0.012).
Among B-cell NHL, patients receiving rituximab-supplemented
chemotherapy (n = 1,356) had a marked reduction of overall
refractory disease (13.6%, including 8.8% of fully refractory and
4.7% of early progression) compared to patients receiving non-
supplemented chemotherapy (n= 1,481), where refractory disease
resulted of 26.7%, including 8.8% of fully refractory and 4.7% of
early progression (p,0.001). As shown in Figure 1, the overall
rate of primary refractory disease was significantly reduced in all
B-cell subtypes when chemotherapy was given with rituximab
addition compared to non-supplemented chemotherapy.
When assayed in multivariate binary logistic regression analysis,
several clinical and therapeutic factors maintained their indepen-
dent association with either fully refractory disease or early
progression or both, as detailed in Table 3.
Long-term outcome
The overall survival curve for the whole series of 3,315 patients
is reported in Figure 2.
The long-term outcome has been then evaluated in the 3,106
patients assessable for response to primary treatment. As of
October 2013, 1,864 (60.0%) were known to be alive, and at a
median follow-up of 7.5 yrs, the 5, 10 and 15 yr. survival
projections were 69.9%, 57.9% and 49.2%, respectively, with a
median survival of 14.6 yrs. Patients with B-cell lymphoma had a
much longer overall survival than those with T-cell subtypes, with
median survival of 15.0 and 6.4 yrs, respectively. Among B-cell
subtypes, the median survival was 25.0, 15.0, and 5.7 yrs, for FL,
DLB-CL, and MCL, respectively (P,0.001). Moreover, B-cell
NHL had a marked survival improvement since the addition of
rituximab to chemotherapy, with a median survival of 11.4 yrs for
patients treated without rituximab, whereas the median survival
has not yet been reached for patients treated with chemotherapy
plus rituximab. For these latter patients, the 5, 10 and 15 yr
Table 2. Raw Incidence of Primary Responsive vs Primary Refractory Disease, According to Main Clinical and Therapeutic Factors,
Among 3,106 Patients Evaluable for Response to First Line Therapy.
Parameter Responsive n = (%) Fully refractory n= (%) Early progression n= (%) p=
all patients 2,416 (77.8) 386 (12.4) 304 (9.8) –
Center
N Bergamo 1,780 (78.3) 274 (12.0) 220 (9.7) 0.509
N Torino 636 (76.4) 112 (13.5) 84 (10.1)
Gender
N Female 1,138 (80.9) 148 (10.5) 121 (8.6) 0.001
N Male 1,278 (75.2) 238 (14.0) 183 (10.8)
Age
N #60 yrs. 1,335 (78.5) 204 (12.0) 161 (9.5) 0.547
N .60 yrs. 1,081 (76.9) 182 (12.9) 143 (10.2)
Main histology I.
N B-cell 2,272 (79.5) 317 (11.1) 269 (9.4) ,0.001
N T-cell 144 (58.1) 69 (27.8) 35 (14.1)
Main histology II.
N int/high-grade 1,605 (75.0) 310 (14.5) 224 (10.5) ,0.001
N low-grade 810 (83.9) 76 (7.9) 80 (8.3)
Ann Arbor Stage
N I–II 900 (87.3) 69 (6.7) 62 (6.0) ,0.001
N III–IV 1,485 (73.3) 302 (14.9) 239 (11.8)
IPI
N 0–2 1,241 (87.4) 92 (6.5) 87 (6.1) ,0.001
N 3–5 669 (67.8) 186 (18.9) 131 (13.3)
LM ratio
N .2.6 1,023 (83.7) 101 (8.3) 98 (8.0) 0.311
N #2.6 625 (77.5) 115 (14.3) 66 (8.2)
BM involvement
N NO 1,434 (82.5) 168 (9.7) 135 (7.8) 0.001
N YES 673 (73.6) 133 (14.6) 108 (11.8)
Chemotherapy schedule
N Conventional chemotherapy 1,961 (77.3) 331 (13.0) 245 (9.7) 0.012
N HDT and autograft 425 (81.0) 44 (8.4) 56 (10.7)
doi:10.1371/journal.pone.0106745.t002
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survival projections are 79.3%, 70.0% and 63.0%, respectively
(data not shown).
Overall, primary responsive patients had a very prolonged life
expectancy, with a median survival of 19.8 yrs., whereas patients
with primary refractory disease had a markedly short survival, as
shown in Figure 3A. Indeed, fully refractory patients had an even
shorter median survival of 10.8 mos., compared to 1.9 yrs for
early progression patients. The favorable outcome of primary
responsive compared to primary refractory patients was reliably
recorded both among patients registered up to 1,999 (Figure 3B)
and those included after 2,000 (Figure 3C). A slight though
significant improvement in life expectancy was observed by
comparing patients registered in the period up to 1,999 vs. those
diagnosed and treated after 2,000, both among primary responsive
patients (median survival 18,2 yrs vs. not reached, respectively)
and early progression patients (median survival 1.75 yrs vs.
2.4 yrs., respectively), whereas no significant differences were seen
among fully refractory patients (median survivals of 0.86 and
0.95 yr, prior and after 2,000, respectively).
The very prolonged survival of responsive patients was equally
observed in B-cell and T-cell subtypes (median survivals: 19.3 yrs
and not reached, for B-cell and T-cell, respectively), as shown in
Figure 4.
The marked difference in survival between primary responsive
and primary refractory patients was consistently observed in all
subtypes, with distinct OS curves according to histology.
Figure 1. Raw Incidence of Primary Responsive vs Primary Refractory Patients Among Main B-Cell Lymphoma Subtypes, According
to Rituximab Administration. Blue = responsive, red= fully refractory, brown=early progression, grey = early death. No Rituximab=Chemother-
apy without Rituximab; Rituximab= chemotherapy supplemented with Rituximab. DLB-CL: Diffuse Large B-Cell Lymphoma; FL: Follicular Lymphoma;
MCL: Mantle-Cell Lymphoma; Miscellaneous B-cell NHL: marginal-zone, small lymphocytic, Burkitt’s and lymphoblastic lymphoma. Data on Rituximab
administration were lacking on 21 out of 2,858 B-cell lymphoma patients. p values were calculated for responsive/refractory ratio in No Rituximab
compared to Rituximab.
doi:10.1371/journal.pone.0106745.g001
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Figures 5 shows the survival curves of the two most represen-
tative main histological subgroups, i.e. intermediate/high and low-
grade lymphoma (see Table 1 for details), according to the two
main periods of patient registration. As shown in Figure 5 A and
B, primary responsive intermediate/high grade lymphoma
patients had a very prolonged survival, with median survival of
17.7 yrs and not reached, for the series up to 1,999 and since
2,000, respectively. The outcome was very poor for primary
refractory patients, with median survival of 1.5 and 2.0 for early
progression patients and 0.7 and 0.9 yrs for fully refractory
patients, in the up to 1,999 and since 2,000 series, respectively.
Figure 5 C and D show the long-term outcome of low-grade
lymphoma patients: again, primary responsive patients had a
prolonged survival, both in the series registered up to 1,999 and
since 2,000, with median survival of 20.8 yrs and not reached,
respectively. Among refractory patients, median survival was of
was 5.2 and 5.6 for early progression patients and 3.0 and 2.7 yrs
Table 3. Multivariate Binary Logistic Regression Analyses on Factors Associated with Refractory Disease.
Parameters associated with: All evaluable patients (n =3,106) B-cell subtype (n= 2,858)
O R1 95% C.I. p= O R1 95% C.I p=
Fully refractory vs responsive disease:
T-cell vs. B-cell histology 1.86 1.06–3.28 0.030 NA NA NA
Int/high vs. low grade histology 1.74 1.09–2.78 0.019 1.71 1.07–2.72 0.024
IPI score 3–5 vs. 0–2 4.18 2.94–5.96 ,0.001 3.74 2.57–5.44 ,0.001
Rituximab adm. Yes vs. No 0.43 0.30–0.62 ,0.001 0.43 0.30–0.62 ,0.001
HDT &autograft Yes vs. No 0.41 0.24–0.72 0.002 0.41 0.22–0.76 0.005
Gender F vs. M 0.74 0.53–1.04 0.085 0.69 0.48–0.99 0.044
LM ratio #2.6 vs.2.6 1.57 1.11–2.23 0.011 1.79 1.24–2.59 0.002
early progression vs responsive disease:
Int/high vs. low grade histology 1.64 0.92–2.90 0.092 1.68 0.94–3.03 0.082
IPI score 3–5 vs. 0–2 2.24 1.36–3.70 0.002 1.99 1.15–3.43 0.014
Rituximab adm. Yes vs. No 0.15 0.09–0.24 ,0.001 1.16 0.10–0.27 ,0.001
BM involvement Yes vs. No 2.26 1.35–3.80 0.002 2.79 1.60–4.87 ,0.001
LM ratio #2.6 vs.2.6 1.47 0.93–2.31 0.099 1.30 0.79–2.15 0.300
HDT &autograft Yes vs. No 0.50 0.24–1.05 0.066 0.46 0.19–1.09 0.078
Gender F vs. M 0.71 0.46–1.11 0.135 0.58 0.35–0.94 0.028
doi:10.1371/journal.pone.0106745.t003
Figure 2. Overall Survival of 3,315 Non-Hodgkin’s Lymphoma (NHL) Patients following first line therapy. At a median follow-up of 7.3
years., the median survival for the entire cohort was of 12.7 yrs. (range: 0–32.6yrs).
doi:10.1371/journal.pone.0106745.g002
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for fully refractory patients, in the up to 1,999 and since 2,000
series, respectively.
Table 4 specifies the main parameters that have independent
prognostic value on overall survival. Primary refractoriness was the
strongest risk factor, with a higher risk for fully refractory disease
compared to early progression. The multivariate Cox proportional
hazard regression analysis on factors affecting the OS was also
performed on the three main B-cell subgroups, DLB-CL, FL, and
MCL. In all subgroups, the high predictive value of primary
refractory disease was confirmed (HR 15.2, 13.7, and 21.5, for
DLB-CL, FL, and MCL, respectively).
Discussion and Conclusions
The availability of databases containing large volumes of data
on lymphoma patients, managed over the last three decades,
allowed us to investigate the role of response to primary treatment
on long-term survival. [18,19,31] A variable proportion of patients
refractory to primary treatment were observed in all lymphoma
subgroups, with the highest frequency amongst T-cell subtypes.
Amongst B-cell lymphoma, a marked reduction in the frequency
of primary refractory disease occurred since the introduction of
rituximab to chemotherapy. Overall, response to primary treat-
ment resulted as the key factor for long-term outcome, with a
median overall survival of 19.8 years for primary responsive
patients, compared to 1.3 years for primary refractory patients.
The series included all evaluable, adult patients that were
managed at the Hematology Centers of Torino and Bergamo over
the last three decades. Our analysis was performed on an
unselected patient population, including all patients older than
14 years, requiring systemic treatment for lymphoma. These
patients represent the common lymphoma population that is
managed with systemic chemotherapy or chemo-immunotherapy
in a hematology Center. [32] B-cell lymphoma was, by far, the
Figure 3. Overall Survival in Non-Hodgkin’s Lymphoma (NHL) Patients according to response to primary therapy. A. Overall survival
(OS) of 3,106 NHL patients diagnosed and managed during the period 1982–2012. The OS projections are of 82.8%, 69.5%, and 59.2%, for responsive
patients, 31.5%, 21.6%, and 15.7% for early progression, 18.9%, 15.2%, and 14.2% for fully refractory patients, at 5, 10, and 15 years, respectively
(responsive vs. refractory: p,0.001). Median follow-up for the whole series is 7.5 yrs (range, 0.6–31.2). B. OS of 1,231 NHL patients diagnosed and
managed up to 1,999. The OS projections are of 81.4%, 68.1%, and 57.6%, for responsive patients, 26.7%, 17.7%, and 12.4% for early progression,
17.6%, 14.8%, and 13.8% for fully refractory patients, at 5, 10, and 15 years, respectively (responsive vs. refractory: p,0.001). Median follow-up for the
whole series is 16 yrs (range, 0.6–31.2) C. OS of 1,875 NHL patients diagnosed and managed since 2,000. The OS projections are of 83.8% and 70.7%,
for responsive patients, 39.1% and 28.4%, for early progression, 20.4% and 14.9%, for fully refractory patients, at 5 and 10 years, respectively
(responsive vs. refractory: p,0.001). Median follow-up for the whole series is 5.1 yrs (range, 0.6–13.7).
doi:10.1371/journal.pone.0106745.g003
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most frequent histological form. In particular, there was a marked
prevalence in the DLB-CL subtype, followed by FL. Thus, the
present analysis reflects the common situations that a hemato-
oncologist faces whenever a patient needs treatment for his newly
diagnosed lymphoma.
Patients showing stable or progressive disease following primary
treatment, or with transient response soon followed by disease
progression within six months since therapy completion, are
usually classified as primary refractory patients. [4,5,13,27,33] All
lymphoma subtypes showed the presence of a variable proportion
of refractory patients, indicating that chemotherapy resistance is a
feature that can occur in both aggressive and indolent lymphoma.
The highest raw incidence of primary refractory disease was found
in the T-cell lymphoma subgroup, with a percentage of refractory
patients as high as 41.9%, confirming that the main problem in the
management of T-cell lymphoma remains the reduced CR/PR
achievement following induction therapy. [2,34,35] Indeed, no
significant differences were observed between T-cell and B-cell
subtypes in the survival curves when the analysis was restricted to
responsive patients. Other clinic-pathological variables that were
associated with either fully refractory disease or early progression
or both were intermediate/high-grade histology, advanced disease
presentation, male gender, BM involvement and low lymphocyte/
monocyte ratio. Interestingly, advanced age over 60 years was not
associated with therapy-resistance. Thus, factors other than disease
refractoriness are likely to be responsible for the poorer outcome of
elderly lymphoma patients compared to patients younger than 60
years.
Among B-cell types, the addition of rituximab brought a
marked fall of refractory disease. This effect was consistently
observed in each histological subtype. Since the introduction of
rituximab in clinical practice, the chemotherapeutic programs
have also been modified, particularly in FL and MCL.
[3,10,24,25] Thus the reduction of refractory disease might be
ascribed to both the high anti-lymphoma activity of rituximab and
to chemotherapy schemes with improved therapeutic efficacy.
However, the treatment schedule for aggressive lymphoma has not
changed remarkably over the last 20 years, as it remains largely
based on the CHOP or CHOP-like schedules.21–23 Thus, at least
in the most frequent DLB-CL subtype, rituximab is mainly
responsible for the reduction of refractory disease, falling from
27.2% to 16.0%, confirming that rituximab front-line is crucial
and may overcome some tumor-associated drug-resistance.
[36,37].
The front-line use of intensive chemotherapy with autograft was
associated with a significant reduction of refractory disease.
However, this had no significant impact on the overall survival
when front-line autograft was evaluated in the multivariate Cox
analysis. The early and late fatal toxicities may have offset the
increased anti-tumor efficacy of autograft-based front-line therapy.
[38] An intensified rescue program with either autologous or
allogeneic transplantation should be early considered in those
patients showing poor response to standard chemo- or chemo-
immunotherapy. At present, there are inadequate data to define
which might be the optimal choice, i.e. autologous vs. allogeneic
transplantion, for patients with chemorefractory disease. Mean-
while, studies are needed in order to develop novel and effective
treatment strategies with reduced toxicity to be employed front-
line in those patients at high risk of primary refractory disease.
The prolonged survival of primary responsive patients is an
impressive, and somewhat unexpected, finding. Both the analysis
of a large patient population and the long-term follow-up have
allowed the first documentation that primary responsive lympho-
ma patients have a global median survival around 19 years. The
median survivals of 25 yrs. for responsive FL and 15 yrs. for
responsive DLB-CL are definitely unanticipated. The long-term
survival is expected to further improve for responsive patients
receiving first-line therapy with rituximab. In fact, patients
managed since 2,000 show survival projections longer compared
to the cohort treated in the period up to 1,999. The survival
Figure 4. OS in responsive lymphoma, according to T-cell vs. B-cell subtype. The OS projections are of 78.9%, 62.5%, and 55.2%, for T-cell
lymphoma patients (median follow up: 10.1 yrs, range, 0.9–26.7), and 83.1%, 69.9%, and 59.5%, for B-cell lymphoma patients (median follow up:
7.5 yrs, range, 0.6–31.2), at 5, 10, and 15 years, respectively (p = 0.326).
doi:10.1371/journal.pone.0106745.g004
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Figure 5. OS in Low-grade and Intermediate/High-grade NHL subtypes according to response to primary therapy. A. OS of 842
Intermediate/High-grade NHL patients diagnosed and managed up to 1,999. The OS projections are of 78.9%, 65.6%, and 57.2%, for responsive
patients, 18.5%, 13.2%, and 9.7% for early progression, 12.3%, 11.4%, and 10.4% for fully refractory patients, at 5, 10, and 15 years, respectively.
Median follow-up for the whole series is 15.9 yrs (range, 0.6–28.9) B. OS of 1,301 Intermediate/High-grade NHL patients diagnosed and managed
since 2,000. The OS projections are of 81.6% and 71.1%, for responsive patients, 30.7% and 25.2% for early progression, 14.3% and 14.3% for fully
refractory patients, at 5 and 10 years, respectively. Median follow-up for the whole series is 5.0 yrs (range, 0.6–13.7) C. OS of 388 Low-grade NHL
patients diagnosed and managed up to 1,999. The OS projections are of 78.0%, 64.0%, and 51.8%, for responsive patients, 51.1%, 31.1%, and 20.8%
for early progression, 36.7%, 26.7%, and 26.7% for fully refractory patients, at 5, 10, and 15 years, respectively. Median follow-up for the whole series is
16.3 yrs (range, 1.7–31.2) D. OS of 574 Low-grade NHL patients diagnosed and managed since 2,000. The OS projections are of 83.5% and 64.2%, for
responsive patients, 60.7% and 36.8% for early progression, 48.4% and 13.2% for fully refractory patients, at 5 and 10 years, respectively. Median
follow-up for the whole series is 5.1 yrs (range, 0.5–13.7). (responsive vs. refractory: p,0.001, in all series).
doi:10.1371/journal.pone.0106745.g005
Table 4. Multivariate Cox Proportional Hazard Regression Analysis on Factors Affecting the Overall Survival.
Parameter associated with survival* All evaluable patients n= 3,106 B-cell subtype n= 2,858
H R2 95% C.I. p= H R2 95% C.I p=
Age.60 yrs 1.66 1.27–2.18 ,0.001 1.76 1.31–2.35 0.001
high vs. low grade histology 2.45 1.76–3.42 ,0.001 2.46 1.76–3.44 ,0.001
IPI score 3–5 vs. 0–2 1.57 1.28–1.92 ,0.001 1.55 1.25–1.91 ,0.001
Rituximab adm. Yes vs. No 0.60 0.49–0.73 ,0.001 0.60 0.49–0.74 ,0.001
Primary Refr.
N fully refr 26.73 18.10–39.47 ,0.001 27.03 17.89–40.84 ,0.001
N Early progr 10.22 7.20–14.50 ,0.001 10.92 7.55–15.81 ,0.001
*treated as time-dependent variables.
doi:10.1371/journal.pone.0106745.t004
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improvements might be ascribed either to the use of rituximab or
to the effective salvage treatments developed in the last decade, or,
possibly, to both of these factors. [1,4,12,26,33] Nevertheless, the
analysis demonstrates that primary responsive patients have a very
favorable outcome. Currently, patients presenting with advanced-
stage B-cell lymphoma have a life expectancy longer than 10 years
if they are responsive to their rituximab-containing, first-line
chemotherapy.
Since 2,000 when rituximab was introduced in the clinical
practice, survival improvements have also been observed for
refractory patients, particularly those with initial, though transient,
response. The current practice is to shift early to intensive
treatments, including autologous or allogeneic transplantation, as
soon as therapy resistance is clinically identified.
[4,5,15,17,19,26,39] These measures are likely responsible for
the improved survival of refractory patients treated in the last 13
years. Nevertheless, the long-term outcome of primary refractory
patients remains poor, particularly those with intermediate/high
grade histology and fully refractory disease. In addition, the Cox
multivariate analysis on the whole series of 3,106 patients indicates
refractory disease as the most predictive factor for the long-term
outcome, with the highest risk associated with fully refractory
disease. The markedly unfavorable prognostic value of primary
unresponsive disease was consistently observed in all subtypes,
including low-grade lymphoma. Thus, achievement of persistent
CR or PR at the initial treatment is the most important prognostic
factor in the management of any lymphoma patient. This finding
has several implications for any future investigation concerning
novel drugs or biosimilar drugs, such as their possible inclusion in
first-line treatment for lymphoma patients. [40].
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